JP2025514763A5 - - Google Patents
Info
- Publication number
- JP2025514763A5 JP2025514763A5 JP2024561852A JP2024561852A JP2025514763A5 JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5 JP 2024561852 A JP2024561852 A JP 2024561852A JP 2024561852 A JP2024561852 A JP 2024561852A JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- multispecific antibody
- amino acid
- antibody according
- constant domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333293P | 2022-04-21 | 2022-04-21 | |
| US63/333,293 | 2022-04-21 | ||
| PCT/US2023/066036 WO2023205753A1 (en) | 2022-04-21 | 2023-04-20 | Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514763A JP2025514763A (ja) | 2025-05-09 |
| JP2025514763A5 true JP2025514763A5 (https=) | 2026-04-28 |
Family
ID=86425985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561852A Pending JP2025514763A (ja) | 2022-04-21 | 2023-04-20 | Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250109207A1 (https=) |
| EP (1) | EP4511398A1 (https=) |
| JP (1) | JP2025514763A (https=) |
| KR (1) | KR20250007564A (https=) |
| CN (2) | CN117597365A (https=) |
| AU (1) | AU2023255761A1 (https=) |
| CA (1) | CA3249454A1 (https=) |
| WO (1) | WO2023205753A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240252601A1 (en) | 2022-12-23 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| GB9824437D0 (en) | 1998-11-06 | 1999-01-06 | Ylo Herttuala Seppo | Gene therapy |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2005049094A1 (en) | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| JP5816170B2 (ja) * | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| CA2822366A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| EP2925785A4 (en) | 2012-11-28 | 2016-11-16 | Zymeworks Inc | MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| CN114786730A (zh) | 2019-11-05 | 2022-07-22 | 再生元制药公司 | N-端scFv多特异性结合分子 |
| CN115551538A (zh) * | 2020-01-21 | 2022-12-30 | 拓维创新生物科技(香港)有限公司 | 干扰IL-1β受体信号转导的药剂 |
-
2022
- 2022-05-03 CN CN202280047414.2A patent/CN117597365A/zh active Pending
-
2023
- 2023-04-20 CA CA3249454A patent/CA3249454A1/en active Pending
- 2023-04-20 AU AU2023255761A patent/AU2023255761A1/en active Pending
- 2023-04-20 US US18/857,898 patent/US20250109207A1/en active Pending
- 2023-04-20 WO PCT/US2023/066036 patent/WO2023205753A1/en not_active Ceased
- 2023-04-20 KR KR1020247038245A patent/KR20250007564A/ko active Pending
- 2023-04-20 JP JP2024561852A patent/JP2025514763A/ja active Pending
- 2023-04-20 EP EP23725348.9A patent/EP4511398A1/en active Pending
- 2023-04-20 CN CN202380048565.4A patent/CN119546637A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP7788113B2 (ja) | Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途 | |
| US12522654B2 (en) | Engineered heterodimeric proteins | |
| Klein et al. | Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies | |
| CA3065868C (en) | Novel hetero-dimeric multi-specific antibody format | |
| KR101851380B1 (ko) | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 | |
| JP2015522525A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| JPWO2020077276A5 (https=) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JPWO2019204646A5 (https=) | ||
| JP2025514763A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JPWO2020154540A5 (https=) | ||
| JP2026064000A (ja) | 抗原結合分子 | |
| RU2025130619A (ru) | Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1) | |
| Fayadat-Dilman | Novel Technologies for Generation of Bispecific Constructs | |
| JPWO2021149053A5 (https=) | ||
| RU2024126644A (ru) | Двухвалентное биспецифическое антитело и способ его получения | |
| NZ793791B2 (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
| Jin et al. | The design and engineering of IgG-like bispecific antibodies | |
| RU2021132277A (ru) | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv | |
| AR122458A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |